Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Gets CE-IVD Mark for QuantStudio Dx System

NEW YORK (GenomeWeb) – Thermo Fisher Scientific announced today that it has received CE-IVD marking for its QuantStudio 5 Dx Real-Time PCR system for sale in Europe.

The instrument's multi-modal software enables users to operate it in either test-development, research-use-only (RUO), or in vitro diagnostic (IVD) mode. Thermo said that the system is designed to benefit clinics, hospitals, and diagnostic test developers performing molecular biology testing using qPCR.

"Today's molecular diagnostic laboratories and developers require high-performing qPCR systems that can be seamlessly adopted into their IVD workflow" Will Geist, vice president and general manager of qPCR for Thermo Fisher, said in a statement.     

The company said that the platform has seen strong adoption since its introduction, but did not elaborate. Earlier this year, Thermo Fisher and Seegene jointly announced a collaboration to file for US Food and Drug Administration approval of Seegene's Allplex diagnostic assay portfolio on the QuantStudio 5 system. In addition, Siemens Healthineers and Thermo Fisher announced an agreement to focus on incorporating the QuantStudio 5 system into Siemen's Atellica MDX 160 Molecular System to provide flexibility and customization to its laboratory workflow.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.